NO984106L - Azolobenzazepin-derivater som neurologisk aktive midler - Google Patents

Azolobenzazepin-derivater som neurologisk aktive midler

Info

Publication number
NO984106L
NO984106L NO984106A NO984106A NO984106L NO 984106 L NO984106 L NO 984106L NO 984106 A NO984106 A NO 984106A NO 984106 A NO984106 A NO 984106A NO 984106 L NO984106 L NO 984106L
Authority
NO
Norway
Prior art keywords
azolobenzazepine
derivatives
active agents
neurologically active
neurologically
Prior art date
Application number
NO984106A
Other languages
English (en)
Norwegian (no)
Other versions
NO984106D0 (no
Inventor
Kelly Anne Brush
Marc Jerome Chapdelaine
William Jackson Frazee
Laura Enid Garcia-Davenport
Joseph James Lewis
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO984106D0 publication Critical patent/NO984106D0/no
Publication of NO984106L publication Critical patent/NO984106L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO984106A 1996-03-08 1998-09-07 Azolobenzazepin-derivater som neurologisk aktive midler NO984106L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1352896P 1996-03-08 1996-03-08
PCT/GB1997/000592 WO1997032883A1 (en) 1996-03-08 1997-03-04 Azolobenzazepine derivatives as neurologically active agents

Publications (2)

Publication Number Publication Date
NO984106D0 NO984106D0 (no) 1998-09-07
NO984106L true NO984106L (no) 1998-11-06

Family

ID=21760422

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984106A NO984106L (no) 1996-03-08 1998-09-07 Azolobenzazepin-derivater som neurologisk aktive midler

Country Status (13)

Country Link
US (2) US6124281A (show.php)
EP (1) EP0888350A1 (show.php)
JP (1) JP2000506160A (show.php)
KR (1) KR19990087585A (show.php)
CN (1) CN1084747C (show.php)
AU (1) AU723860B2 (show.php)
CA (1) CA2247453A1 (show.php)
IL (1) IL126095A0 (show.php)
NO (1) NO984106L (show.php)
NZ (1) NZ330973A (show.php)
TW (1) TW486480B (show.php)
WO (1) WO1997032883A1 (show.php)
ZA (1) ZA971964B (show.php)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016770A1 (en) * 1997-09-29 1999-04-08 Meiji Seika Kaisha, Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
ATE410427T1 (de) * 2001-12-26 2008-10-15 Meiji Seika Kaisha Neues kristallines tricyclisches triazolobenzazepinderivat
CA2486446A1 (en) * 2002-02-07 2003-08-14 Neurogen Corporation Substituted fused pyrazolecarboxylic acid arylamides and related compounds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
KR20120091275A (ko) 2004-05-14 2012-08-17 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 방법
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR101741168B1 (ko) 2008-12-22 2017-05-29 밀레니엄 파머슈티컬스 인코퍼레이티드 오로라 키나아제 억제제 및 항­ｃｄ 항체의 병용
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
CN104031049A (zh) 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
ES2156933T3 (es) * 1993-12-28 2001-08-01 Meiji Seika Co Derivados triciclicos de benzazepina y benzotiazepina.
US6093714A (en) * 1995-06-15 2000-07-25 Meiji Seika Kaisha, Ltd. Tricyclic benzazepine compounds

Also Published As

Publication number Publication date
CA2247453A1 (en) 1997-09-12
AU2225397A (en) 1997-09-22
NZ330973A (en) 2000-03-27
KR19990087585A (ko) 1999-12-27
IL126095A0 (en) 1999-05-09
CN1224424A (zh) 1999-07-28
US6124281A (en) 2000-09-26
AU723860B2 (en) 2000-09-07
WO1997032883A1 (en) 1997-09-12
EP0888350A1 (en) 1999-01-07
ZA971964B (en) 1997-09-08
TW486480B (en) 2002-05-11
JP2000506160A (ja) 2000-05-23
CN1084747C (zh) 2002-05-15
US6313290B1 (en) 2001-11-06
NO984106D0 (no) 1998-09-07

Similar Documents

Publication Publication Date Title
NO984106L (no) Azolobenzazepin-derivater som neurologisk aktive midler
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
NO983749L (no) CCR-3 reseptor-antagonister
HUP0001062A2 (hu) NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények
BE1002212A5 (fr) Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments.
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
NO994452L (no) Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
DK165447C (da) 2-pyrimidinyl-1-piperazin-derivater, fremgangsmaader til deres fremstilling og laegemidler indeholdende dem
HUP9801340A1 (hu) Triciklusos pirazolszármazékok és az azokat tartalmazó gyógyszerkészítmények
DK0484573T3 (da) Physostigmin-beslægtede 4- og 6-carbamater, en fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
SE8405754D0 (sv) 7-karboximetoxi-furo-(3,4-c)-pyridinderivat, framstellning derav och terapeutiska kompositioner innehallande dem
TR200103349T2 (tr) Purin türevleri, hazırlama usulü ve bunları içeren ispençiyari bileşimleri.
DK158087D0 (da) Hidtil ukendte benzothiazinderivater og sammensaetning indeholdende samme
SI1216245T1 (en) Pharmaceutically active sulfonyl hydrazide derivatives
NO20000957L (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
NO965444L (no) Triterpen-derivat samt medikamentell sammensetning omfattende dette
NO904801L (no) Fremgangsmaate for fremstilling av acat-inhibitorer.
MX9803730A (es) Nuevo proceso de preparacion de derivados de fenilimidazolidina.
FR2696466B1 (fr) Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
MA26721A1 (fr) Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
NO995594D0 (no) Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application